https://de.marketscreener.com/kurs/aktie/OLIPASS-CORPORATION-103508961/news/OliPass-Corporation-geht-in-die-zweite-Phase-der-Phase-2a-Studie-fur-das-Schmerzmittel-OLP-1002-ub-41020890/?utm_source=telegram&utm_medium=social&utm_campaign=share